Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasm

Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasm

Abstract: Intensifying induction by combining venetoclax with a high-dose cytarabine regimen may improve outcomes for high-risk populations such as adult patients with adverse-risk newly diagnosed or relapsed acute myeloid leukemia. In a phase 1 trial testing the novel combination of venetoclax and...

Full description

Saved in:

Bibliographic Details
Main Authors:	Suravi Raychaudhuri, Ted A. Gooley, Allegra Rasmussen, Kim Quach, Eva Gill, Anna B. Halpern, Jacob S. Appelbaum, Cristina M. Ghiuzeli, Paul C. Hendrie, Ryan D. Cassaday, Roland B. Walter, Mary-Elizabeth M. Percival
Format:	Article
Language:	English
Published:	Elsevier 2025-08-01
Series:	Blood Neoplasia
Online Access:	http://www.sciencedirect.com/science/article/pii/S2950328025000202
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Selinexor combination with decitabine and half-dose CMG (Cytarabine+ Mitoxantrone+G-CSF) in Patients with refractory/relapsed acute myeloid leukemia (AML) previously exposed to Venetoclax: a single-center retrospective study
by: Zi-Yu Zhao, et al.
Published: (2025-01-01)

Successful Treatment of Multifocal Histiocytic Sarcoma Occurring after Renal Transplantation with Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) Followed by Allogeneic Hematopoietic Stem Cell Transplantation
by: Julia Tomlin, et al.
Published: (2015-01-01)

Venetoclax combination with Cladribine, idarubicin, Cytarabine for relapsed T-Cell acute lymphoblastic leukemia/lymphoblastic lymphoma treatment: A case report and literature review
by: Alaa Eldein Yahia, et al.
Published: (2025-01-01)

Low Dose Cytarabine and Cladribine for Treatment of Relapsed or Refractory Acute Myeloid Leukemia: Clinical Experience
by: SV Gritsaev, et al.
Published: (2016-01-01)

Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with <i>BCR::ABL1</i>-negative B-cell / myeloid mixed phenotype acute leukemia
by: Roberta S. Azevedo, et al.
Published: (2025-06-01)

Iron overload mediates cytarabine resistance in AML by inhibiting the TP53 signaling pathway
by: Jia Yan, et al.
Published: (2025-02-01)

Investigating resistance to 5-Azacytidine and Venetoclax in PDX models of MDS/AML
by: Petra Bašová, et al.
Published: (2025-01-01)

Daunorubicin, Cytarabine, and Cladribine Regimen Plus Radiotherapy and Donor Lymphocyte Infusion for Extramedullary Relapse of Acute Myeloid Leukemia after Hematopoietic Stem Cell Transplantation
by: Marco Sanna, et al.
Published: (2013-01-01)

Prognostic significance of monocytic-like phenotype in patients with AML treated with venetoclax and azacytidine
by: Lin-Pierre Zhao, et al.
Published: (2025-07-01)

Safety run-in and part 1 of GIMEMA AML1718: venetoclax combined with FLAI as induction treatment in non–low-risk AML
by: Giovanni Marconi, et al.
Published: (2025-05-01)

GDF-15 upregulates the SLC7A11/GPX4 signaling axis and promotes mitoxantrone resistance in AML cells
by: Qian-wei Lu, et al.
Published: (2025-06-01)

Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia
by: N Yalman, et al.
Published: (2000-07-01)

Venetoclax schedule in AML: 7 vs 14 vs 21 vs 28 days
by: Naseema Gangat, et al.
Published: (2025-04-01)

The association of FAT1 mutations with therapeutic outcomes in AML, especially in receiving venetoclax combination
by: Tao Wang, et al.
Published: (2025-03-01)

(R)-WAC-224, a new anticancer quinolone, combined with venetoclax and azacitidine overcomes venetoclax-resistant AML through MCL-1 downregulation
by: Hiroshi Ureshino, et al.
Published: (2025-05-01)

Venetoclax with low-dose cytarabine, a forgotten combination in patients with acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review
by: Lauro Fabián Amador-Medina, et al.
Published: (2024-12-01)

Treatment discontinuation due to toxicity for patients with acute myeloid leukemia receiving intensive chemotherapy
by: Suravi Raychaudhuri, et al.
Published: (2025-08-01)

PPARγ-induced upregulation of fatty acid metabolism confers resistance to venetoclax and decitabine therapy in AML
by: Kotoko Yamatani, et al.
Published: (2025-08-01)

Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients
by: Christophe Willekens, et al.
Published: (2025-04-01)

Venetoclax and azacitidine for molecular relapse after intensive chemotherapy in NPM1 or CBF AML: a FILO study
by: Jules Higué, et al.
Published: (2025-08-01)

ONC213: a novel strategy to resensitize resistant AML cells to venetoclax through induction of mitochondrial stress
by: Jenna L. Carter, et al.
Published: (2025-01-01)

Venetoclax combined with escalating doses of homoharringtonine, low-dose cytarabine, and granulocyte colony-stimulating factor demonstrates feasibility and tolerability for remission induction in pediatric acute myeloid leukemia
by: Shengqin Cheng, et al.
Published: (2025-03-01)

Acute myeloid leukaemia induced by mitoxantrone: case report Leucemia mielóide aguda induzida por mitoxantrone: relato de caso
by: Walter Oleschko Arruda, et al.
Published: (2005-06-01)

VENETOCLAX-BASED VERSUS 7+3 INDUCTION THERAPY IN FIT YOUNGER ADULTS WITH NEWLY DIAGNOSED NON-CBF AML
by: Dmitrii Zhogolev, et al.
Published: (2025-07-01)

Targeting HASPIN kinase disrupts SR protein–mediated RNA splicing and synergizes with BCL-2 inhibitor venetoclax in AML
by: Mengdan Liu, et al.
Published: (2025-08-01)

Response to cladribine in patient with systemic mastocytosis
by: Radojković Milica, et al.
Published: (2011-01-01)

Mitoxantrone in secondarily progressive multiple sclerosis: a series of 18 patients Mitoxantrone na esclerose múltipla secundária progressiva relato de 18 casos
by: María Belén Montú, et al.
Published: (2005-06-01)

Cladribine tablets in the new multiple sclerosis era
by: Fabio Buttari, et al.
Published: (2025-06-01)

A combination of Dihydroartemisinin and Venetoclax enhances antitumor effect in AML via C-MYC/BCL-XL/MCL-1 triple targeting
by: Fenglin Li, et al.
Published: (2025-04-01)

Performing a physiologically relevant test for cladribine tablets
by: P. A. Losenkova, et al.
Published: (2024-09-01)

Cladribine Ameliorates Imiquimod Induced Murine Psoriasiform Dermatitis
by: Xue J, et al.
Published: (2025-02-01)

Hand foot syndrome associated with standard dose cytarabine
by: Atul Sharma, et al.
Published: (2013-01-01)

Identifying Cladribine prescription pattern in MS: an Italian multicentre study
by: Aurora Zanghì, et al.
Published: (2025-01-01)

Physiological and histological effects of apigenin and luteolin on Cytarabine injected rats
by: Ghada A. Taqa, et al.
Published: (2024-01-01)

The clinical application of mitoxantrone hydrochloride tracing in endoscopic radical resection of thyroid carcinoma
by: Xiaozhou Cheng, et al.
Published: (2025-07-01)

Effects of the mitoxantrone thermosensitive liposome nanodelivery system on prostate cancer in vivo and in vitro
by: Yuan Gao, et al.
Published: (2025-05-01)

Experience of treatment of hairy cell leukemia with new drug Vero-cladribine
by: Yu. E. Ryabukhina, et al.
Published: (2022-11-01)

Long-term impact of oral cladribine on humoral immunity in multiple sclerosis
by: Marc Messner, et al.
Published: (2025-08-01)

Vitamin C effect on mitoxantrone-induced cytotoxicity in human breast cancer cell lines.
by: Eliana Guerriero, et al.
Published: (2014-01-01)

Imposed Optical Defocus Induces Isoform-Specific Up-Regulation of TGFβ Gene Expression in Chick Retinal Pigment Epithelium and Choroid but Not Neural Retina.
by: Yan Zhang, et al.
Published: (2016-01-01)